Twist Bioscience Corporation 90184D100 US90184D1000 02/05/2026 To adopt, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers, as described in the Proxy Statement under "Executive Compensation." SECTION 14A SAY-ON-PAY VOTES ISSUER 1131281 107637 FOR 1131281 FOR Simulations Plus, Inc. 829214105 US8292141053 02/11/2026 Approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended, to increase the number of shares authorized for issuance thereunder from 2,500,000 shares to 3,450,000 shares of common stock of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 1907500 0 FOR 1907500 FOR Trisalus Life Sciences, Inc 89680M101 US89680M1018 05/14/2026 To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4472963 0 FOR 4472963 FOR Trisalus Life Sciences, Inc 89680M101 US89680M1018 05/14/2026 To consider and vote upon, on an advisory basis, the frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 4472963 0 FOR 4472963 FOR Atricure, Inc. 04963C209 US04963C2098 05/18/2026 Advisory vote on the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 700479 0 FOR 700479 FOR Atricure, Inc. 04963C209 US04963C2098 05/18/2026 Proposal to approve an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000. SECTION 14A SAY-ON-PAY VOTES ISSUER 700479 0 FOR 700479 FOR Atricure, Inc. 04963C209 US04963C2098 05/18/2026 Proposal to approve an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,500,000. SECTION 14A SAY-ON-PAY VOTES ISSUER 700479 0 FOR 700479 FOR Koru Medical Systems, Inc. 759910102 US7599101026 05/19/2026 Advisory approval of the compensation of the Company's executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 8474731 0 FOR 8474731 FOR Koru Medical Systems, Inc. 759910102 US7599101026 05/19/2026 Advisory approval on the frequency of future votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 8474731 0 FOR 8474731 FOR Koru Medical Systems, Inc. 759910102 US7599101026 05/19/2026 Approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares. SECTION 14A SAY-ON-PAY VOTES ISSUER 8474731 0 FOR 8474731 FOR Omnicell, Inc. 68213N109 US68213N1090 05/19/2026 Proposal to approve an amendment to the Omnicell, Inc. 2009 Equity Incentive Plan, as amended, to, among other items, add an additional 1,600,000 shares to the number of shares of common stock authorized for issuance under such plan. SECTION 14A SAY-ON-PAY VOTES ISSUER 471127 0 FOR 471127 FOR Omnicell, Inc. 68213N109 US68213N1090 05/19/2026 Say on Pay - An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 471127 0 FOR 471127 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/20/2026 To approve the Company's 2023 Long-Term Incentive Plan, as amended, to, among other things, increase the number of shares authorized for issuance under the plan. SECTION 14A SAY-ON-PAY VOTES ISSUER 1190540 72224 FOR 1190540 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/20/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1190540 72224 FOR 1190540 FOR Neogenomics, Inc. 64049M209 US64049M2098 05/21/2026 Approval of the Second Amendment of the NeoGenomics, Inc. 2023 Equity Incentive Plan. SECTION 14A SAY-ON-PAY VOTES ISSUER 9091979 5022 FOR 9091979 FOR Neogenomics, Inc. 64049M209 US64049M2098 05/21/2026 Approval, on a non-binding advisory basis, of the Compensation Paid to the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 9091979 5022 FOR 9091979 FOR Vera Therapeutics, Inc. 92337R101 US92337R1014 05/21/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 300623 0 FOR 300623 FOR Establishment Labs Holdings Inc G31249108 VGG312491084 05/22/2026 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 294246 0 FOR 294246 FOR iRhythm Technologies, Inc. 450056106 US4500561067 05/27/2026 To approve the adoption of our 2026 Equity Incentive Plan. SECTION 14A SAY-ON-PAY VOTES ISSUER 105581 56536 FOR 105581 FOR iRhythm Technologies, Inc. 450056106 US4500561067 05/27/2026 To approve, on a non-binding advisory basis, the named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 105581 56536 FOR 105581 FOR Si-Bone, Inc. 825704109 US8257041090 06/04/2026 Advisory vote to approve executive compensation "Say-on-Pay". SECTION 14A SAY-ON-PAY VOTES ISSUER 5395980 16921 FOR 5395980 FOR Edgewise Therapeutics Inc 28036F105 US28036F1057 06/04/2026 Conduct an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 878654 0 FOR 878654 FOR Amylyx Pharmaceuticals, Inc. 03237H101 US03770N1019 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 3092866 0 FOR 3092866 FOR Tectonic Therapeutic, Inc. 878972108 US8789721086 06/08/2026 Advisory approval of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 622289 0 FOR 622289 FOR Apogee Therapeutics, Inc 03770N101 US03770N1019 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 537675 0 FOR 537675 FOR Enliven Therapeutics, Inc. 29337E102 US29337E1029 06/09/2026 To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 343559 0 FOR 343559 FOR Enliven Therapeutics, Inc. 29337E102 US29337E1029 06/09/2026 To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 343559 0 FOR 343559 FOR Mimedx Group, Inc 602496101 US6024961012 06/10/2026 Advisory approval of executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 1470434 0 FOR 1470434 FOR Palvella Therapeutics, Inc. 697947109 US6979471090 06/10/2026 Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares. SECTION 14A SAY-ON-PAY VOTES ISSUER 750908 0 FOR 750908 FOR Palvella Therapeutics, Inc. 697947109 US6979471090 06/10/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 750908 0 FOR 750908 FOR Palvella Therapeutics, Inc. 697947109 US6979471090 06/10/2026 Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 750908 0 FOR 750908 FOR 908 Devices Inc 65443P102 US65443P1021 06/11/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4089278 1082660 FOR 4089278 FOR 908 Devices Inc 65443P102 US65443P1021 06/11/2026 To hold an advisory vote on the frequency of holding future non-binding advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4089278 1082660 FOR 4089278 FOR Centessa Pharmaceuticals PLC 152309100 US1523091007 06/12/2026 To receive and approve, on an advisory basis, the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2025, which is set forth as Annex A to the attached proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1498188 0 FOR 1498188 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/15/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 345112 0 FOR 345112 FOR Guardant Health Inc 40131M109 US40131M1099 06/17/2026 Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 236895 0 FOR 236895 FOR Guardant Health Inc 40131M109 US40131M1099 06/17/2026 Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 236895 0 FOR 236895 FOR Genedx Holdings Corp. 81663L200 US81663L2007 06/18/2026 Approval, on a non-binding advisory basis, the compensation of our named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 226116 0 FOR 226116 FOR Genedx Holdings Corp. 81663L200 US81663L2007 06/18/2026 Indicate, on a non-binding advisory basis, whether future advisory votes on the compensation paid by us to our named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 226116 0 FOR 226116 FOR Butterfly Network, Inc. 124155102 US1241551027 06/18/2026 To approve by a non-binding advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1160322 1038845 FOR 1160322 FOR Crinetics Pharmaceuticals Inc. 22663K107 US22663K1079 06/18/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission SECTION 14A SAY-ON-PAY VOTES ISSUER 1477022 0 FOR 1477022 FOR Axogen, Inc. 05463X106 US05463X1063 06/23/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 3516254 0 FOR 3516254 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2026 Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 78272 0 FOR 78272 FOR Health Catalyst, Inc. 42225T107 US42225T1079 07/09/2025 To approve, on an advisory, non-binding basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 11523422 0 FOR 11523422 FOR